fda tirzepatide news says compounding pharmacies can keep making weight-loss med tirzepatide, for now FDA Ends Compounded GLP-1s: What

Ozempic and Wegovy: Hype or Helpful

Severe Side effects: Sometimes, Tirzepatide can cause serious side effects

Amaral DC, Guedes J, Cruz MRB, et al

A research-grade peptide & longevity library

The FDA initially approved ritonavir for treating HIV and reported that more than 16% of people experienced dysgeusia during clinical trials

The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising